Literature DB >> 15778453

Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein).

Celia P Martínez-Jiménez1, M José Gómez-Lechón, José V Castell, Ramiro Jover.   

Abstract

CCAAT/enhancer-binding proteins (C/EBPs) are key transcription factors involved in the constitutive expression of several cytochrome P450 genes in the liver. Their concentration and activity change in several pathophysiological conditions. For instance, during inflammation, released cytokines induce repressive C/EBPbeta-liver inhibitory protein (LIP), which antagonizes constitutive C/EBP transactivators [C/EBPalpha and C/EBPbeta-liver activating protein (LAP)], down-regulating genes such as CYP3A4. However, the mechanism by which hepatic C/EBP factors modulate transcription of the CYP3A4 gene is not known. To elucidate the mechanism of action, we cotransfected luciferase reporter vectors, containing 5'-flanking deletions of the CYP3A4 gene, along with expression vectors for C/EBPbeta-LAP, C/EBPbeta-LIP, and C/EBPalpha, in hepatic (HepG2) and nonhepatic (HeLa) cells. Analysis of the -3557 to -6954 base pair (bp) region demonstrated the existence of a 288-bp sequence at -5.95 kilobases (kb), which showed maximal response to C/EBPbeta-LAP ( approximately 30-fold increase in HepG2 cells). Coexpression of LAP with increasing amounts of LIP reduced the activating effect by approximately 70%. Site-directed mutagenesis of predicted C/EBPbeta binding sites demonstrated the presence of four functional C/EBPbeta-responsive motifs within this distal flanking region. Further experiments using chromatin immunoprecipitation proved the binding of endogenous C/EBPbeta to the -5.95-kilobase enhancer of the CYP3A4 gene in human hepatocytes. Expression of recombinant LAP and LIP by means of adenoviral vectors resulted in their binding to this region, which was followed by activation/repression of CYP3A4. Together, our results uncover a new distal enhancer site in the CYP3A4 gene where C/EBPbeta-LAP binds and activates transcription, whereas the truncated form, C/EBPbeta-LIP, antagonizes LAP activity and causes gene repression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778453     DOI: 10.1124/mol.104.008169

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Novel CYP2C9 promoter variants and assessment of their impact on gene expression.

Authors:  Melissa A Kramer; Allan E Rettie; Mark J Rieder; Erwin T Cabacungan; Ronald N Hines
Journal:  Mol Pharmacol       Date:  2008-02-29       Impact factor: 4.436

2.  Distinct functions of CCAAT enhancer-binding protein isoforms in the regulation of manganese superoxide dismutase during interleukin-1beta stimulation.

Authors:  Xiaolei Qiu; Kimberly J Aiken; Ann L Chokas; Dawn E Beachy; Harry S Nick
Journal:  J Biol Chem       Date:  2008-06-17       Impact factor: 5.157

3.  CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: application to the development of a metabolically competent human hepatic cell model.

Authors:  Marta Benet; Agustín Lahoz; Carla Guzmán; José V Castell; Ramiro Jover
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

Review 4.  Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors:  Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-22       Impact factor: 4.481

Review 5.  Current concepts of follicle-stimulating hormone receptor gene regulation.

Authors:  Jitu W George; Elizabeth A Dille; Leslie L Heckert
Journal:  Biol Reprod       Date:  2010-08-25       Impact factor: 4.285

Review 6.  The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.

Authors:  Jiezhong Chen; Kong-Nan Zhao; Chen Chen
Journal:  Ann Transl Med       Date:  2014-01

7.  Human hepatic UGT2B15 developmental expression.

Authors:  Karthika Divakaran; Ronald N Hines; D Gail McCarver
Journal:  Toxicol Sci       Date:  2014-06-30       Impact factor: 4.849

Review 8.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

9.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

10.  Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Authors:  Vishal Lamba; John C Panetta; Stephen Strom; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.